Endogenous Control Mechanisms of FAK and PYK2 and Their Relevance to Cancer Development
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Focal adhesion kinase (FAK) and its close paralogue, proline-rich tyrosine kinase 2 (PYK2), are key regulators of aggressive spreading and metastasis of cancer cells. While targeted small-molecule inhibitors of FAK and PYK2 have been found to have promising antitumor activity, their clinical long-term efficacy may be undermined by the strong capacity of cancer cells to evade anti-kinase drugs. In healthy cells, the expression and/or function of FAK and PYK2 is tightly controlled via modulation of gene expression, competing alternatively spliced forms, non-coding RNAs, and proteins that directly or indirectly affect kinase activation or protein stability. The molecular factors involved in this control are frequently deregulated in cancer cells. Here, we review the endogenous mechanisms controlling FAK and PYK2, and with particular focus on how these mechanisms could inspire or improve anticancer therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nagata, S., & Golstein, P. (1995) · Science · doi:10.1126/science.7533326 · Cited by 3,979
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681
Restoration of p53 function leads to tumour regression in vivo
Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820 · cited 1×
“However, therapeutic restoration of a functional p53 pool at endogenous levels can have tumor-suppressive effects [146].”
BackgroundHSP90 at the hub of protein homeostasis: emerging mechanistic insights
Taipale, M., Jarosz, D. F., & Lindquist, S. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2918 · Cited by 1,818
Integrin-mediated signal transduction linked to Ras pathway by GRB2 binding to focal adhesion kinase
Schlaepfer, D. D., Hanks, S. K., Hunter, T., & Geer, P. V. D. (1994) · Nature · doi:10.1038/372786a0 · Cited by 1,595 · cited 1×
“However, FAK Y925 phosphorylation also links FAK activation via Grb2 to activation of the RAS pathway [164], and FAK signaling is a requirement for the maintenance of KRAS-dependent adenocarcinomas [165].”
Backgroundp53 mutant mice that display early ageing-associated phenotypes
Tyner, S. D., Venkatachalam, S., Choi, J., Jones, S., Ghebranious, N., Igelmann, H., Lu, X., Soron, G., Cooper, B., Brayton, C., et al. (2002) · Nature · doi:10.1038/415045a · Cited by 1,459 · cited 1×
“While loss or damage of p53 is closely associated with the development of tumors, forced overexpression can cause premature aging [145].”
BackgroundFAK in cancer: mechanistic findings and clinical applications
Sulzmaier, F. J., Jean, C., & Schlaepfer, D. D. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3792 · Cited by 1,381 · cited 5×
“However, the efficacy and specificity of these inhibitors remain low in several cases, and their exact mechanism of action is not always well understood [10,215].”
BackgroundInfluentialAn atlas of human long non-coding RNAs with accurate 5′ ends
Hon, C.-C., Ramilowski, J. A., Harshbarger, J., Bertin, N., Rackham, O. J. L., Gough, J., Denisenko, E., Schmeier, S., Poulsen, T. M., Severin, J., et al. (2017) · Nature · doi:10.1038/nature21374 · Cited by 1,007 · cited 1×
“Moreover, the biological capacities of the almost 20,000 potentially functional human lncRNAs are only beginning to emerge [225].”
BackgroundQuantitative Analysis of Hsp90-Client Interactions Reveals Principles of Substrate Recognition
Taipale, M., Krykbaeva, I., Koeva, M., Kayatekin, C., Westover, K. D., Karras, G. I., & Lindquist, S. (2012) · Cell · doi:10.1016/j.cell.2012.06.047 · Cited by 879 · cited 5×
“Thus, chaperones maintain cellular proteins in their functional state and prevent their degradation [127,128].”
BackgroundInfluentialDuncan, J. S., Whittle, M. C., Nakamura, K., Abell, A. N., Midland, A. A., Zawistowski, J. S., Johnson, N. L., Granger, D. A., Jordan, N. V., Darr, D. B., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.053 · Cited by 732
Atomic structure of Hsp90-Cdc37-Cdk4 reveals that Hsp90 traps and stabilizes an unfolded kinase
Verba, K. A., Wang, R. Y.-R., Arakawa, A., Liu, Y., Shirouzu, M., Yokoyama, S., & Agard, D. A. (2016) · Science · doi:10.1126/science.aaf5023 · Cited by 424
Nuclear FAK Controls Chemokine Transcription, Tregs, and Evasion of Anti-tumor Immunity
Serrels, A., Lund, T., Serrels, B., Byron, A., McPherson, R. C., von Kriegsheim, A., Gómez-Cuadrado, L., Canel, M., Muir, M., Ring, J. E., et al. (2015) · Cell · doi:10.1016/j.cell.2015.09.001 · Cited by 407 · cited 1×
“Consequently, promising preclinical results were obtained when FAK inhibitors were administered in combination with BRAF inhibitors or used jointly with chemotherapy, radiotherapy [12] or immunotherapy [13,14].”
BackgroundEndothelial-cell FAK targeting sensitizes tumours to DNA-damaging therapy
Tavora, B., Reynolds, L. E., Batista, S., Demircioglu, F., Fernandez, I., Lechertier, T., Lees, D. M., Wong, P.-P., Alexopoulou, A., Elia, G., et al. (2014) · Nature · doi:10.1038/nature13541 · Cited by 163 · cited 1×
“Consequently, promising preclinical results were obtained when FAK inhibitors were administered in combination with BRAF inhibitors or used jointly with chemotherapy, radiotherapy [12] or immunotherapy [13,14].”
BackgroundDourlen, P., Fernandez-Gomez, F. J., Dupont, C., Grenier-Boley, B., Bellenguez, C., Obriot, H., Caillierez, R., Sottejeau, Y., Chapuis, J., Bretteville, A., et al. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.59 · Cited by 118
FAK inhibitors in Cancer, a patent review
Lv, P.-C., Jiang, A.-Q., Zhang, W.-M., & Zhu, H.-L. (2018) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2018.1414183 · Cited by 114 · cited 1×
“However, the efficacy and specificity of these inhibitors remain low in several cases, and their exact mechanism of action is not always well understood [10,215].”
BackgroundGiralt, A., Brito, V., Chevy, Q., Simonnet, C., Otsu, Y., Cifuentes-Díaz, C., de Pins, B., Coura, R., Alberch, J., Ginés, S., et al. (2017) · Nature Communications · doi:10.1038/ncomms15592 · Cited by 102
PTK2B/Pyk2 overexpression improves a mouse model of Alzheimer's disease
Giralt, A., de Pins, B., Cifuentes-Díaz, C., López-Molina, L., Farah, A. T., Tible, M., Deramecourt, V., Arold, S. T., Ginés, S., Hugon, J., et al. (2018) · Experimental Neurology · doi:10.1016/j.expneurol.2018.05.020 · Cited by 64
Self-citationmiR-1298 Inhibits Mutant KRAS-Driven Tumor Growth by Repressing FAK and LAMB3
Zhou, Y., Dang, J., Chang, K.-Y., Yau, E., Aza-Blanc, P., Moscat, J., & Rana, T. M. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2936 · Cited by 54
Cited by
Targeting FAK in anticancer combination therapies
Dawson, J. C., Serrels, A., Stupack, D. G., Schlaepfer, D. D., & Frame, M. C. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00340-6 · Cited by 384
Heparanase, cell signaling, and viral infections
Koganti, R., Suryawanshi, R., & Shukla, D. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03559-y · Cited by 67
Bastin, J., Sroussi, M., Nemazanyy, I., Laurent-Puig, P., Mouillet-Richard, S., & Djouadi, F. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04341-x · Cited by 24
Palhano Zanela, T. M., Woudenberg, A., Romero Bello, K. G., & Underbakke, E. S. (2023) · Structure · doi:10.1016/j.str.2023.02.003 · Cited by 12
Molecularly imprinted nanoparticles reveal regulatory scaffolding features in Pyk2 tyrosine kinase
Zanela, T. M. P., Zangiabadi, M., Zhao, Y., & Underbakke, E. S. (2024) · RSC Chemical Biology · doi:10.1039/d3cb00228d · Cited by 3
Metadata
- Authors
- Naser, R., Aldehaiman, A., Díaz-Galicia, E., & Arold, S. T.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2018-06-11
- Volume
- 10
- Issue
- 6
- Pages
- 196
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W2806313922
- Cited by
- 90
- References
- 18
- FWCI
- 4.84
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.